At the start of this year, I observed that shares of Gilead Sciences, Inc. (NASDAQ:GILD) saw a downwards re-rating after the company started 2024 on a soft note. A setback in its pipeline, a softer ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: Jefferies London Healthcare ...

Truist analyst Asthika Goonewardene raised the firm’s price target on Gilead (GILD) to $97 from $83 and keeps a Hold rating on the ...

Maxim downgraded Gilead (GILD) to Hold from Buy. The stock has appreciated significantly following a pullback in the first half of the year, ...

Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...

AstraZeneca and Amgen's drug could have a new use after positive Phase 3 study results. Elsewhere, Jazz set new plans for a ...

Gilead Sciences, Inc. (NASDAQ:GILD) Q3 2024 Earnings Call Transcript November 6, 2024 Gilead Sciences, Inc. beats earnings expectations. Reported EPS is $2.02, expectations were $1.53. Operator: Good ...

The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers ...

An ex-Gilead worker who says he was illegally fired for refusing to steal confidential material isn’t protected by a ...

Headquartered in Foster City, California, Gilead Sciences, Inc. (GILD) is a prominent biopharmaceutical company with a market cap of $114.2 billion. Gilead specializes in developing and delivering ...

The China International Import Expo has consistently demonstrated China's strong commitment to promoting high-level openness ...

A Pennsylvania federal district court denied summary judgment to Gilead Sciences, Inc. on the wrongful discharge claim under state law of an employed at-will therapeutic specialist who sold its ...